The first participant was vaccinated on Friday in Tumaini, a Phase 2/3 clinical trial of vaccines against Bundibugyo virus, in Bunia in the Democratic Republic of the Congo, CEPI (opens in new tab) and the Institute of Tropical Medicine Antwerp (opens in new tab) said. Bunia is the capital of Ituri province, the epicenter of the outbreak, AFP (opens in new tab) reported. There is currently no approved vaccine to protect against Bundibugyo virus, according to ITM.

The first vaccine in the trial is Ervebo, which is licensed against the Zaire species of Ebola. The trial will test whether it offers cross-protection against Bundibugyo, AFP (opens in new tab) reported. Two Bundibugyo-specific candidates funded by CEPI (opens in new tab), under development by Moderna and by the University of Oxford with the Serum Institute of India, are expected to enter the trial “shortly,” CEPI (opens in new tab) said. Candidates will be given through ring vaccination, which focuses on contacts at high risk of infection, according to ITM. The trial will include pregnant women and children aged 12 and older, as well as children from one year of age for Ervebo.

“Science gives us hope. Today, in Bunia DRC, the first participants were vaccinated in a new Ebola vaccine trial called Tumaini, which means ‘hope’ in Swahili,” WHO Director-General Tedros Adhanom Ghebreyesus said on X, AFP (opens in new tab) reported. “If successful, this would be the first time we have clear evidence of vaccine efficacy against Bundibugyo virus -- a major advance that could transform how we respond to this outbreak and prepare for future outbreaks and help save lives,” said Chikwe Ihekweazu, executive director of the WHO Health Emergencies Programme, according to AFP (opens in new tab).

“Bringing this trial into the Ebola response is an important step towards addressing the urgent needs of affected communities,” said Steve Ahuka-Mundeke, the incident manager of the DRC’s Ebola response. The INRB and the University of Antwerp co-lead and co-sponsor the trial, and Gavi has committed up to $40 million to fund manufacturing readiness, ITM said.

The WHO counted 9,704 confirmed cases, including 4,687 deaths, as of Oct. 20, an overall fatality rate of 48.3%. CEPI (opens in new tab) and ITM gave figures of 9,552 cases and 4,602 deaths as of Oct. 21. CEPI (opens in new tab) said the trial will evaluate the safety, immunogenicity and efficacy of the vaccine candidates.

Update, Oct. 27: The World Health Organization (opens in new tab) said on Tuesday that four people were vaccinated when the trial launched on Friday, according to Anadolu Agency (opens in new tab) and the United Nations' summary of the WHO's Geneva briefing. Meg Doherty, the WHO's director of science for health, who spoke from Bunia, said the trial is testing whether Ervebo reduces severe disease or death rather than whether it prevents infection, Anadolu reported. The UN summary of her answers to reporters differs, saying the trial is looking at vaccine efficacy to see whether it prevented new infections, and that it is based on the number of events that occurred or were prevented. The vaccine's effect on Bundibugyo virus disease is unknown; Ervebo is known to be safe and effective against Ebola caused by the Zaire virus.

Two vaccination rings are in place and several more are being prepared, Doherty said. Eligible participants can be vaccinated between one and 21 days after exposure, and researchers do not yet know whether the timing affects outcomes, Anadolu reported. She said community members were walking into the site asking to be enrolled. “We do not yet know for certain when results will begin to emerge. We expect it will take several months,” Doherty said, according to Anadolu. The UN summary said thousands of people could eventually take part.

WHO advisory groups reviewed the two Bundibugyo-specific vaccines last week, Oxford's ChAdOx1, developed with the Serum Institute of India, and Moderna's mRNA-1469, and their recommendations are expected this week, Doherty said. The UN summary said the WHO hopes to begin adding those two vaccines to the trial by mid-November. It said there is no information yet on how well either works, because both are new and were developed rapidly.